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THE CHALLENGE OF DOSE ESCA-
LATION FOR NON-SMALL CELL
LUNG CANCER (NSCLC):
A PARADOXAL ISSUE
Van Houtte P., Roelandts M., Mahin C.
Institut Jules Bordet, Brussels, Belgium
The loco-regional control of NSCLC
remains a major challenge but it is a
requirement for cure: classical radiation
schedule delivering dose in the range of
60 to 65 Gy yield a very poor local control
(less than 20%). Recent trials have clearly
demonstrate that it was possible to
improve the local control and this translate
in a clear survival benefit. This was
observed with accelerated hyperfra-
ctionated radiation (CHART and HART)
but also with concurrent chemo-radiothe-
rapy approach (Furuse, Schaake-Koning
trials). The recent major technological
development both in treatment planning
and radiation delivery has opened the road
to look for an escalation in the total
radiation dose far above the past threshold
dose of 65 Gy. What have we learned from
the current experience? It is possible to go
above this limit of 65 Gy but doses
escalation is often limited by the tolerance
of normal tissues especially the amount of
irradiated normal lung. To overcome this
restriction, the current philosophy is to
treat only the gross tumor volume and to
avoid any elective nodal irradiation. This
implies to have a good mediastinal eva-
luation (PET is particularly useful). Indeed,
nodal failures are reported to be a rare
event while controlling the primary tumor
remains the challenge. Doses as high as
90 Gy can be delivered but there is a
paradoxal issue: this is often only possible
for small tumors probably not requiring this
high dose while larger tumors can not be
treated to this level. The second problem
is the issue of repopulation: increasing
treatment duration by only using daily 2 Gy
per fraction will certainly not be as
effective as expected: the only solution is
either using an hyperfractionating sche-
dule or higher daily dose (concomitant
boost technique). Additional studies are
clearly needed to see the real impact of
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this approach on a large population scale
and not only to very select patients able to
follow the guidelines for very complicate
set-up (the different gating techniques).
Furthermore, longer follow-up will be
needed to assess the possible late effects
at the level of the lung and the heart. Last
but not least, this technique should be in a
next step be part of a multimodal
approach.
15.
COMBINED CHEMOTHERAPY AND
RADIATION IN LOCALLY
ADVANCED INOPERABLE NSCLC
Jassem J.
Medical University of Gdansk, Poland
Lung cancer is the leading cause of
cancer death around the world. Non-small
cell lung cancer (NSCLC) accounts for
three quarters of all lung tumors. Surgery
is the cornerstone of treatment in localized
NSCLC but only 20% of patients are con-
sidered surgical candidates at presen-
tation. The vast majority of patients cannot
be subjected to surgery either because of
tumor advancement or poor medical
condition. Radiation therapy has tradi-
tionally been considered the mainstay of
treatment in inoperable stage III disease.
Irradiation, however, is in principle used for
palliation since in most instances this
method does not allow for eradication of
bulky disease in the thorax. Moreover,
radiotherapy does not prevent uncontrolled
systemic disease, which is the major
cause of death in locally advanced
NSCLC. In consequence, the prognosis of
patients with locally advanced tumours is
dismal and has remained essentially
unchanged within the last decades. The
five-year survival rates after irradiation
vary between 3 and 6%. One of the
attempts to improve the outcome is
combining radiation with chemotherapy.
This strategy seems to be particularly
interesting as it may potentially increase
the cure rate not only by improved
locoregional tumour control but also by
elimination of micrometastases outside the
radiotherapy field. Chemotherapy and
radiation may be applied in sequence or
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concurrently. The results of phase III trials
of radiation alone vs combined therapy
using platinum based regimens demon-
strated some survival benefit. The positive
impact of chemotherapy was also demon-
strated in the metaanalysis. Of the two
strategies (chemotherapy followed by
radiotherapy or concurrent chemoradio-
therapy, the latter was found to be superior
to sequential application but at the
expense of increased early toxicity. The
value of new agents (taxanes, vinorelbine,
gemcitabine and topoisomerase inhibitors)
in combined modality therapy of NSCLC
seems to be promising, but warrants
further clinical evaluation. In conclusion,
chemotherapy may be useful as an
adjunct to radiation in locally advanced
NSCLC. However, the benefit of combined
approach, in particular concomitant che-
moradiation, should be balanced against
increased toxicity.
16.
WYNIKI BADAN KlINICZNYCH
- ROZWAZANIA, WJ\TPLIWOSCI
Hliniak A.
Centrum Onkologii - Instytut
Warszawa-Ursyn6w
W latach 2000-2002 ogtosilismy (A. Hli-
niak i wsp6tp.) trzy opracowania dotyczqce
radioterapii raka krtani (1. Radiotherapy
Oncology 62 2002-1-10; 2. Nowotwory 52
(2002) Nr 2 -111; 3. Nowotwory 51 (2001-
4-381 ).
Cel badania - rozwazania i wqtpliwosci
lekarza dotyczqce wniosk6w wynikajqcych
z tych doniesien
1. "Skr6cenie ,catkowitego ,czasu leczenia
o 7 dni nie wptyn~o na popraw~ wy-
nik6w leczenia w spos6b istotny sta-
tystycznie (p-0.37).
Uwagi - w pierwszych miesiqcach
po leczeniu niepewna ocena wylecze-
nia (obrz~k, stan zapalny, zmiany mar-
twicze) - zwtaszcza w badaniach wie-
loosrodkowych (r6zne doswiadczenie
oceniajqcych). Wyniki leczenia stajq
si~ wiarygodne po 8-12 miesiqcach
od zakonczenia terapii.
2. Chorzy leczeni wyzszymi dawkami
rokujq gorzej. Potwierdzajq to uwagi
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szeregu autor6w (Batani, Szutkowski
etc.), ze wyzsze dawki stosuje si~
u chorych gorzej rokujqcych z wqtpliwq
regresjq guza. Podanie wyzszych
dawek tqczy si~ z wydtuzeniem catko-
witego czasu leczenia. Moze to w spo-
s6b istotny wptynqc na bt~dnq ocen~
zaleznosci dawka czas i duzq r6znic~
w ocenie tego czynnika w opracowa-
niach retrospektywnych (Fowler).
3. Wyniki u chorych leczonych konwen-
cjonalnie w badaniu prospektywnym Sq
lepsze 0 15% niz w retrospektywnym
(nadselekcja chorych?)
1, 2, 3. Stromy przebieg krzywych wyle-
czalnosci w pierwszych 8-12 miesiqcach
po zakonczeniu radioterapii moze prowa-
dzic do zbyt optymistycznych ocen nowych
metod leczenia, r6wniez kojarzonego
(RT+chth?).
17.
ESTRO IN TIMES OF CHOLERA
Heeren G..
Project Development and Public Relations,
ESTRO Office, Ave E.Mounierlaan 83,
1.200 Brussels
In the past five years ESTRO has known
a period of dynamic development.
Membership figures show a steep growth
curve. ESTRO meetings grew in size and
quality. The offer of teaching courses
nearly doubled. The citation index and
number of papers submitted to the green
journal went up dramatically. In a single
year all 4 of the applications for EU sup-
port submitted to the European Commi-
ssion were funded. ESTRO extended its
cooperatIon networks far beyond the own
specialty: seeking strategic alliances with
international organisations (such as IAEA),
the EU and estranged family members
such as radiology, nuclear medicine and
basic science. Building on a broad basis of
active members, the Society felt com-
fortable in a leading position within the
Federation of European Cancer Societies.
ESTRO was also successful in setting up
European infrastructures for verifying the
accuracy of dosimetry in European
radiotherapy departments and assuring
the quality of radiotherapy trials.
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